KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Average (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Equity Average for 15 consecutive years, with $276.4 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 32.31% to $276.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $276.4 million through Dec 2025, down 32.31% year-over-year, with the annual reading at $206.3 million for FY2025, 7.82% down from the prior year.
  • Equity Average for Q4 2025 was $276.4 million at Halozyme Therapeutics, down from $418.3 million in the prior quarter.
  • The five-year high for Equity Average was $423.0 million in Q1 2025, with the low at $93.7 million in Q2 2021.
  • Average Equity Average over 5 years is $236.9 million, with a median of $214.7 million recorded in 2021.
  • The sharpest move saw Equity Average crashed 60.81% in 2023, then surged 223.41% in 2025.
  • Over 5 years, Equity Average stood at $239.3 million in 2021, then crashed by 44.26% to $133.4 million in 2022, then rose by 24.81% to $166.5 million in 2023, then soared by 145.21% to $408.3 million in 2024, then crashed by 32.31% to $276.4 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $276.4 million, $418.3 million, and $407.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.